Genetic regulation of osteoclast development and function

Nature Reviews Genetics

Volumn 4, Issue 8, 2003, Pages 638-649

  Teitelbaum, Steven L ^a   Ross, F Patrick ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANKYRIN; ENZYME PRECURSOR; ESTROGEN; OSTEOPROTEGERIN; PROTEASOME; PROTEIN; PROTEIN P62; PROTON PUMP; RANKL PROTEIN; UNCLASSIFIED DRUG;

ALBERS SCHOENBERG DISEASE; BONE DISEASE; BONE MARROW; BONE REMODELING; BRAIN CALCIFICATION; CELL FUNCTION; CELL LINE; CELL MATURATION; CELL POLARITY; CORTICAL BONE; DENDRITIC CELL; FOCAL ADHESION; FOUNDER EFFECT; GAIN OF FUNCTION MUTATION; GENE; GENE CONTROL; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; ION TRANSPORT; KIDNEY TUBULE ACIDOSIS; METACHROMATIC CEMENT LINE; MULTINUCLEAR CELL; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; POLKARYON; PRIORITY JOURNAL; REVIEW; SCLEROSIS; SHIP GENE; SIGNAL TRANSDUCTION; THROMBOCYTE; TNFRSF11A GENE; TNFRSF11B GENE;

ANIMALS; BONE AND BONES; BONE REMODELING; CARRIER PROTEINS; CELL LINEAGE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GLYCOPROTEINS; HUMANS; IONS; MEMBRANE GLYCOPROTEINS; MODELS, BIOLOGICAL; MUTATION; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 0043267732     PISSN: 14710056     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrg1122     Document Type: Review

References (126)

1. Blair, H. C., Teitelbaum, S. L., Ghiselli, R. & Gluck, S. Osteoclastic bone resorption by a polarized vacuolar proton pump. Science 245, 855-857 (1989).
2. Coccia, P. F. et al. Successful bone-marrow transplantation for infantile malignant osteopetrosis. N. Engl. J. Med. 302, 701-708 (1980).
3. Udagawa, N. et al. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc. Natl Acad. Sci. USA 87, 7260-7264 (1990).
4. Sly, W. S. et al. Carbonic anhydrase 11 deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. N. Engl. J. Med. 313, 139-145 (1985).
5. Tondravi, M. M. et al. Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. Nature 386, 81-84 (1997).
6. Henkel, G. W., McKercher, S. R., Leenen, P. J. M. & Maki, R. A. Commitment to the monocytic lineage occurs in the absence of the transcription factor PU.1. Blood 93, 2849-2858 (1999).
7. Luchin, A. et al. Genetic and physical interactions between microphthalmia transcription factor and PU.1 are necessary for osteoclast gene expression and differentiation. J. Biol. Chem. 276, 36703-36710 (2001).
8. Rehli, M., Lichanska, A., Cassady, A. I., Ostrowski, M. C. & Hume, D. A. TFEC is a macrophage-restricted member of the microphthalmia-TFE subfamily of basic helix-loop-helix leucine zipper transcription factors. J. Immunol. 162, 1559-1565 (1999).
9. Walker, D. G. Bone resorption restored in osteopetrotic mice by transplants of normal bone marrow and spleen cells. Science 190, 784-785 (1975).
10. Walker, D. G. Spleen cells transmit osteopetrosis in mice. Science 190, 785-787 (1975).
11. Thesingh, C. W. & Scherft, J. P. Fusion disability of embryonic osteoclast precursor cells and macrophages in the microphthalmic osteopetrotic mouse. Bone 6, 43-52 (1985).
12. Luchin, A. et al. The microphthalmia transcription factor regulates expression of the tartrate-resistant acid phosphatase gene during terminal differentiation of osteoclasts. J. Bone Miner. Res. 15, 451-460 (2000).
13. McGill, G. G. et al. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 109, 707-718 (2002).
14. Steingrimsson, E. et al. Molecular basis of mouse microphthalmia (mi) mutations helps explain their developmental and phenotypic consequences. Nature Genet. 8, 256-263 (1994).
15. Weilbaecher, K. N. et al. Age-resolving osteopetrosis: a rat model implicating microphthalmia and the related transcription factor TFE3. J. Exp. Med. 187, 775-785 (1998).
16. Moore, K. J. Insight into the microphthalmia gene. Trends Genet. 11, 442-448 (1995).
17. Nii, A., Steingrimsson, E., Copeland, N. G., Jenkins, N. A. & Ward, J. M. Mild osteopetrosis in the microphthalmia-oak ridge mouse: a model for intermediate autosomal recessive osteopetrosis in humans. Am. J. Pathol. 147, 1871-1882 (1995).
18. Cielinski, M. J. & Marks, S. C. Bone metabolism in the osteopetrotic rat mutation microphthalmia blanc. Bone 16, 567-574 (1995).
19. Yao, G.-Q., Sun, B. H., Weir, E. C. & Insogna, K. L. A role for cell-surface CSF-1 in osteoblast-mediated osteoclastogenesis. Calcif. Tissue Int. 70, 339-346 (2002).
20. Yoshida, H. et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345, 442-444 (1990).
21. Myint, Y. Y. et al. Granulocyte/macrophage colony-stimulating factor and interleukin-3 correct osteopetrosis in mice with osteopetrosis mutation. Am. J. Pathol. 154, 553-566 (1999).
22. Niida, S. et al. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J. Exp. Med. 190, 293-298 (1999).
23. Insogna, K. L. et al. Colony-stimulating factor-1 induces cytoskeletal reorganization and c-src-dependent tyrosine phosphorylation of selected cellular proteins in rodent osteoclasts. J. Clin. Invest. 100, 2476-2485 (1997).
24. Grey, A., Chen, Y., Paliwal, I., Carlberg, K. & Insogna, K. Evidence for a functional association between phosphatidylinositol 3-kinase and c-src in the spreading response of osteoclasts to colony-stimulating factor-1. Endocrinology 141, 2129-2138 (2000).
25. Dai, X.-M. et al. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood 99, 111-120 (2002).
26. Feng, X. et al. Tyrosines 559 and 807 in the cytoplasmic tail of the m-csf receptor play distinct roles in osteoclast differentiation and function. Endocrinology 143, 4868-4874 (2002).
27. Lacey, D. L. et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176 (1998). Perhaps the most important study of osteoclastogenesis, in which RANKL (OPGL) is shown to be the main osteoclastogenic cytokine both in vitro and in vivo.
28. Yasuda, H. et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl Acad. Sci. USA 95, 3597-3602 (1998).
29. Li, J. et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl Acad. Sci. USA 97, 1566-1571 (2000).
30. Simonet, W. S. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309-319 (1997). This important paper identifies OPG as an anti-osteoclastogenic molecule the overexpression of which leads to osteopetrosis, and the administration of which prevents experimental post-menopausal osteoporosis.
31. Thomas, G. P., Baker, S. U. K., Eisman, J. A. & Gardiner, E. M. Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. J. Endocrinol. 170, 451-460 (2001).
32. Bucay, N. et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12, 1260-1268 (1998).
33. Ross, F. P. RANKing the importance of measles virus in Paget's disease. J. Clin. Invest. 105, 555-558 (2000).
34. Darnay, B. G., Ni, J., Moore, P. A. & Aggarwal, B. B. Activation of NF-κB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-κB-inducing kinase. J. Biol. Chem. 274, 7724-7731 (1999).
35. Galibert, L. et al. The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signalling mechanisms of receptor activator of NFκB, a member of the TNFR superfamily. J. Biol. Chem. 273, 34120-34127 (1998).
36. Armstrong, A. P. et al. A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J. Biol. Chem. 277, 44347-44356 (2002).
37. Lomaga, M. A. et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 13, 1015-1024 (1999),
38. Naito, A. et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 4, 353-362 (1999).
39. Ye, H. et al. Distinct molecular mechanism for initiating TRAF6 signalling. Nature 418, 443-447 (2002).
40. Burgess, T. L. et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J. Cell Biol. 145, 527-538 (1999).
41. Ishida, N. et al. Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J. Biol. Chem. 277, 41147-41156 (2002).
42. Takayanagi, H. et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3, 889-901 (2002).
43. Franzoso, G. et al. Requirement for NFκB in osteoclast and B-cell development. Genes Dev. 11, 3482-3496 (1997). This study establishes the NFκB-signalling pathway as essential for osteoclastogenesis and shows that the event requires either the p50 or p52 subunit of the transcription complex.
44. Jimi, E. et al. Activation of NFκB is involved in the survival of osteoclasts promoted by interleukin-1. J. Biol. Chem. 273, 8799-8805 (1998).
45. Miyazaki, T. et al. Reciprocal role of ERK and NFκB pathways in survival and activation of osteoclasts. J. Cell Biol. 148, 333-342 (2000).
46. Abu-Amer, Y., Dowdy, S. F., Ross, F. P., Clohisy, J. C. & Teitelbaum, S. L. TAT fusion proteins containing tyrosine 42-deleted IκBα arrest osteoclastogenesis. J. Biol. Chem. 276, 30499-30503 (2001).
47. David, J.-P., Sabapathy, K., Hoffmann, O., Idarraga, M. H. & Wagner, E. F. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and-independent mechanisms. J. Cell Sci. 115, 4317-4325 (2002).
48. Grigoriadis, A. E. et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266, 443-448 (1994).
49. Miyamoto, T. et al. Bifurcation of osteoclasts and dendritic cells from common progenitors. Blood 98, 2544-2554 (2001).
50. Matsuo, K. et al. Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nature Genet. 24, 184-187 (2000). In this study, the authors establish that RANKL recruits osteoclasts in an AP-1 dependent manner in which c-Fos, which is required for osteoclastogenesis, induces the transcription of Fosl1.
51. Fleischmann, A. et al. Fra-1 replaces c-Fos-dependent functions in mice. Genes Dev. 14, 2695-2700 (2000).
52. McHugh, K. P. et al. Mice lacking β3 integrins are osteosclerotic because of dysfunctional osteoclasts. J. Clin. Invest. 105, 433-440 (2000). The authors establish that the αvβ3 integrin is a candidate anti-osteoporosis therapeutic target, as mice with their β3 gene deleted have dysfunctional osteoclasts and develop osteopetrosis.
53. Engleman, V. W. et al. A peptidomimetic antagonist of the αvβ3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J. Clin. Invest. 99, 2284-2292 (1997).
54. Aubin, J. E. Osteoclast adhesion and resorption: the role of podosomes. J. Bone Miner. Res. 7, 365-368 (1992).
55. Feng, X. et al. A Glanzmann's mutation of the β3 integrin gene specifically impairs osteoclast function. J. Clin. Invest. 107, 1137-1144 (2001).
56. Faccio, R., Zallone, A., Ross, F. P. & Teitelbaum, S. L. c-Fms and the αvβ3 integrin collaborate during osteoclast differentiation. J. Clin. Invest. 111, 749-758 (2003).
57. Sanjay, A. et al. Cbl associates with Pyk2 and Src to regulate Src kinase activity, αvβ3 integrin-mediated signaling, cell adhesion, and osteoclast motility. J. Cell Biol. 152, 181-196 (2001).
58. Pfaff, M. & Jurdic, P. Podosomes in osteoclast-like cells: structural analysis and cooperative roles of paxillin, proline-rich tyrosine kinase 2 (Pyk2) and integrin αvβ3. J. Cell Sci. 114, 2775-2786 (2001).
59. Duong, L. T. et al. Inhibition of osteoclast function by adenovirus expressing antisense protein-tyrosine kinase 2. J. Biol. Chem. 276, 7484-7492 (2001).
60. Yokouchi, M. et al. Src-catalyzed phosphorylation of c-Cbl leads to the interdependent ubiquitination of both proteins. J. Biol. Chem. 276,35185-35193 (2001).
61. Lee, P. S. W. et al. The Cbl protooncoprotein stimulates CSF-1 receptor multiubiquitination and endocytosis, and attenuates macrophage proliferation. EMBO J. 18, 3616-3628 (1999).
62. Wang, Y., Yeung, Y.-G. & Stanley, E. R. CSF-1 stimulated multiubiquitination of the CSF-1 receptor and of Cbl follows their tyrosine phosphorylation and association with other signaling proteins. J. Cell. Biochem. 72, 119-134 (1999).
63. Soriano, P., Montgomery, C., Geske, R. & Bradley, A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64, 693-702 (1991).
64. Boyce, B. F., Yoneda, T., Lowe, C., Soriano, P. & Mundy, G. R. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J. Clin. Invest. 90, 1622-1627 (1992).
65. -/- mutant mice. Genes Dev. 11, 2835-2844 (1997).
66. Duong, L. T. et al. PYK2 in osteoclasts is an adhesion kinase, localized in the sealing zone, activated by ligation of α(v)β3 integrin, and phosphorylated by src kinase. J. Clin. Invest. 102, 881-892 (1998).
67. Mattsson, J. P. et al. Isolation and reconstitution of a vacuolar-type proton pump of osteoclast membranes. J. Biol. Chem. 269, 24979-24982 (1994).
68. Teitelbaum, S. L. Bone resorption by osteoclasts. Science 289, 1504-1508 (2000).
69. Sly, W. S., Hewett-Emmett, D., Whyte, M. P., Yu, Y.-S. & Tashian, R. E. Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc. Natl Acad. Sci. USA 80, 2752-2756 (1983).
70. +-ATPase cause infantile malignant osteopetrosis. Hum. Mol. Genet. 9, 2059-2063 (2000).
71. +-adenosine triphosphatase in a Japanese patient with infantile malignant osteopetrosis. Bone 30, 436-439 (2002).
72. +ATPase.
73. Scimeca, J.-C. et al. The gene encoding the mouse homologue of the human osteoclast-specific 116-kDa V-ATPase subunit bears a deletion in osteosclerotic (oc/oc) mutants. Bone 26, 207-213 (2000).
74. Li, Y. P., Chen, W., Liang, Y., Li, E. & Stashenko, P. Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification. Nature Genet. 23, 447-451 (2000).
75. Abu-Amer, Y., Ross, F. P., Schlesinger, P., Tondravi, M. M. & Teitelbaum, S. L. Substrate recognition by osteoclast precursors induces s-crc/microtubule association. J. Cell Biol. 137, 247-258 (1997).
76. Schlesinger, P. H., Blair, H. C., Teitelbaum, S. L. & Edwards, J. C. Characterization of the osteoclast ruffled border chloride channel and its role in bone resorption. J. Biol. Chem. 272, 18636-18643 (1997).
77. Kornak, U. et al. Loss of the CIC-7 chloride channel leads to osteopetrosis in mice and man. Cell 104, 205-215 (2001). The authors establish that mice and humans that lack a chloride channel in the osteoclast ruffled membrane fail to acidify the resorptive microenvironment, and so develop osteopetrosis.
78. Gelb, B. D., Shi, G. P., Chapman, H. A. & Desnick, R. J. Pycnodysostosis, a lysosomal disease caused by cathepsin-K deficiency. Science 273, 1236-1238 (1996).
79. Saftig, P. et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc. Natl Acad. Sci. USA 95, 13453-13458 (1998). Consistent with the fact that cathepsin K deficiency is responsible for the bone-sclerosing disorder pycnodysostosis, the authors find mice that lack the enzyme have osteopetrosis owing to the failure of osteoclasts to degrade the collagenous component of bone.
80. Nishi, Y. et al. Determination of bone markers in pycnodysostosis: effects of cathepsin-K deficiency on bone matrix degradation. J. Bone Miner. Res. 14, 1902-1908 (1999).
81. Motyckova, G. et al. Linking osteopetrosis and pycnodysostosis: regulation of cathepsin-K expression by the microphthalmia transcription factor family. Proc. Natl Acad. Sci. USA 98, 5798-5803 (2001).
82. Dodds, R. A. et al. Human osteoclast cathepsin-K is processed intracellularly prior to attachment and bone resorption. J. Bone Miner. Res. 16, 478-486 (2001).
83. Garnero, P. et al. The collagenolytic activity of cathepsin-K is unique among mammalian proteinases. J. Biol. Chem. 273, 32347-32352 (1998).
84. Zaidi, M., Troen, B., Moonga, B. S. & Abe, E. cathepsin-K, osteoclastic resorption, and osteoporosis therapy. J. Bone Miner. Res. 16, 1747-1749 (2001).
85. Lark, M. W. et al. A potent small molecule, nonpeptide inhibitor of cathepsin-K (SB 331750) prevents bone matrix resorption in the ovariectomized rat. Bone 30, 746-753 (2002).
86. Anderson, D. M. et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390, 175-179 (1997).
87. Hughes, A. E. et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nature Genet. 24, 45-48 (2000). This report provided the first evidence for mutations in RANK and documented their capacity to lead to enhanced osteoclastogenesis by autonomous activation of signals downstream of RANK.
88. Haslam, S. I. et al. Paget's disease of bone: evidence for a susceptibility locus on chromosome 18q and for genetic heterogeneity. J. Bone Miner. Res. 13, 911-917 (1998).
89. Whyte, M. P. & Hughes, A. E. Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J. Bone Miner. Res. 17, 26-29 (2002).
90. Whyte, M. P. et al. Osteoprotegerin deficiency and juvenile Paget's disease. N. Engl. J. Med. 347, 175-184 (2002). The authors elegantly show that deletion of the gene for OPG in humans, which is the decoy receptor for RANKL, results in greatly increased activation of RANK and hence bone resorption.
91. Hofbauer, L. C. & Schoppet, M. Osteoprotegerin deficiency and juvenile Paget's disease. N. Engl. J. Med. 347, 1622-1623 (2002).
92. Cundy, T. et al. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum. Mol. Genet. 11, 2119-2127 (2002).
93. Laurin, N., Brown, J. P., Morissette, J. & Raymond, V. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am. J. Hum. Genet. 70, 1582-1588 (2002).
94. Hocking, L. J. et al. Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. Hum. Mol. Genet. 11, 2735-2739 (2002). An important study showing that Paget disease of bone can arise as a result of mutations of an adaptor protein that couples RANK to more distal signalling events.
95. Geetha, T. & Wooten, M, W. Association of the atypical protein kinase C-interacting protein p62/ZIP with nerve growth factor receptor TrkA regulates receptor trafficking and Erk5 signaling. J. Biol. Chem. 278, 4730-4739 (2003).
96. Moscat, J. & Diaz-Meco, M. T. The atypical protein kinase Cs: functional specificity mediated by specific protein adapters. EMBO Rep. 1, 399-403 (2000).
97. Rohrschneider, L. R., Fuller, J. F., Wolf, I., Liu, Y. & Lucas, D. M. Structure, function, and biology of SHIP proteins. Genes Dev 14, 505-520 (2000).
98. March, M. E. & Ravichandran, K. Regulation of the immune response to SHIP. Semin. Immunol. 14, 37-47 (2002).
99. Helgason, C. D. et al. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev. 12, 1610-1620 (1998).
100. Takeshita, S. et al. SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts. Nature Med. 8, 943-949 (2002). The first genetic evidence that derangements in phosphoinositide metabolism can lead to greater bone loss as a result of increased osteoclast number and activity.
101. Ware, M. D. et al. Cloning and characterization of human SHIP, the 145-kD inositol 5-phosphatase that associates with SHC after cytokine stimulation. Blood 88, 2833-2840 (1996).
102. Khosla, S., Melton, L. J. & Riggs, B. L. Estrogen and the male skeleton. J. Clin. Endocrinol. Metab. 87, 1443-1450 (2002).
103. Pacifici, R. et al. Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release. Proc. Natl Acad. Sci. USA 86, 2398-2402 (1989).
104. Pacifici, R. et al. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc. Natl Acad. Sci. USA 88, 5134-5138 (1991).
105. Lorenzo, J. A. et al. Mice lacking the type 1 interleukin-1 receptor do not lose bone mass after ovariectomy. Endocrinology 139, 3022-3025 (1998).
106. Ammann, P. et al. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J. Clin. Invest. 99, 1699-1703 (1997).
107. Roggia, C. et al. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc. Natl Acad. Sci. USA 98, 13960-13965 (2001).
108. Kimble, R. B. et al. Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1 and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production. J. Biol. Chem. 271, 28890-28897 (1996).
109. Cenci, S., Weitzmann, M. N., Gentile, M. A., Aisa, M. C. & Pacifici, R. M-CSF neutralization and Egr-1 deficiency prevent ovariectomy-induced bone loss. J. Clin. Invest. 105, 1279-1287 (2000).
110. Cenci, S. et al. Estrogen deficiency induces bone loss by enhancing T cell production of TNFα. J. Clin. Invest. 106, 1229-1237 (2000).
111. Lam, J. et al. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106, 1481-1488 (2000).
112. Cenci, G. et al. Estrogen deficiency causes bone loss by upregulating T cell proliferation and lifespan through IFNγ-induced class II transactivator. Proc. Natl Acad. Sci. USA (in the press).
113. Eghbali-Fatourechi, G. et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J. Clin. Invest. 111, 1221-1230 (2003).
114. Takayanagi, H. et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ. Nature 408, 600-605 (2000).
115. Takayanagi, H, et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β. Nature 416, 744-749 (2002).
116. Passeri, G., Girasole, G., Jilka, R. L. & Manolagas, S. C. Increased interleukin-6 production by murine bone marrow and bone cells after estrogen withdrawal. Endocrinology 133, 822-828 (1993).
117. Jilka, R. L. et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 257, 88-91 (1992).
118. Kawasaki, K. et al. Osteoclasts are present in gp130-deficient mice. Endocrinology 138, 4959-4965 (1997).
119. Choi, S. J. et al. Antisense inhibition of macrophage inflammatory protein 1-α blocks bone destruction in a model of myeloma bone disease. J. Clin. Invest. 108, 1833-1841 (2001).
120. Horwood, N. J. et al. Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. J. Clin. Invest. 101, 595-603 (1998).
121. Wei, S., Wang, M. W., Teitelbaum, S. L. & Ross, F. P. Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-κB and MAP kinase signaling. J. Biol. Chem. 21, 6622-6630 (2001).
122. Udagawa, N. et al. Interleukin-18 (interferon-γ-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-γ to inhibit osteoclast formation. J. Exp. Med. 185, 1005-1012 (1997).
123. Horwood, N. J., Elliott, J., Martin, T. J. & Gillespie, M. T. IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. J. Immunol. 166, 4915-4921 (2001).
124. Faccio, R., Novack, D. V., Zallone, A., Ross, F. P. & Teitelbaum, S. L. Dynamic changes in the osteoclast cytoskeleton in response to growth factors and cell attachment are controlled by b3 integrin. J. Cell Biol. (in the press).
125. Kong, Y. Y. et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315-323 (1999).
126. Ross, F. P. Interleukin 7 and estrogen-induced bone loss. Trends Endocrinol. Metab. 14, 147-149 (2003).